Condition: Essential Thrombocythemia · Sponsor: Incyte Corporation
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Banner Md Anderson Cancer Center | Gilbert, Arizona, United States | Not Yet Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Not Yet Recruiting |
| City of Hope Medical Center | Duarte, California, United States | Not Yet Recruiting |
| Marin Cancer Care | Greenbrae, California, United States | Recruiting |
| University of California, Los Angeles Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Not Yet Recruiting |
| UCSF | San Francisco, California, United States | Withdrawn |
| Rocky Mountain Cancer Centers-Lone Tree | Lone Tree, Colorado, United States | Not Yet Recruiting |
| Medstar Georgetown Medical Center, Inc | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Florida Cancer Specialists & Research Institute | Fort Myers, Florida, United States | Not Yet Recruiting |
| University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Not Yet Recruiting |
| Cleveland Clinic | Weston, Florida, United States | Not Yet Recruiting |
+ 168 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.